ArticleBMC infectious diseases2026
Association between GLP-1 receptor agonist use and risk of pneumonia and pyothorax in type 2 diabetes: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTo assess the association between Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and the incidence of pneumonia and pyothorax in patients with Type 2 diabetes mellitus (T2DM). T2DM is associated with an increased risk of pneumonia and its complications, including pyothorax. GLP-1 RAs, a class of antidiabetic medications, have demonstrated anti-inflammatory and cardiometabolic benefits, but their influence on infectious complications remains underexplored.
methodsThis retrospective cohort study was conducted using data from the TriNetX U.S. collaborative network, which comprises electronic health records of over 116 million patients. Adults aged ≥ 20 years with a new diagnosis of type 2 diabetes mellitus (T2DM) between 2016 and 2023 were identified. Patients were divided into two groups based on exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus non-GLP-1 RA treatments. After applying exclusion criteria and performing 1:1 propensity score matching for demographics, comorbidities, medications, and relevant laboratory values, a total of 181,634 patients were included in the matched cohorts. The primary outcome was the incidence of pneumonia (ICD-10-CM codes J12-J18) and pyothorax (ICD-10-CM code J86).
resultsThe incidence of pneumonia and pyothorax was significantly lower in the GLP-1 RA group (15.20%) compared to the non-GLP-1 RA group (18.54%), with a hazard ratio (HR) of 0.76 (95% CI: 0.74-0.78). GLP-1 RA use was also associated with reduced risk of pyothorax (HR = 0.58, 95% CI: 0.46-0.73). These protective effects were consistent across subgroups stratified by age, sex, race, and BMI, although not statistically significant among Asian and African American populations, likely due to limited sample size.
conclusionsGLP-1 RA therapy in T2DM patients is associated with a significantly lower risk of pneumonia and pyothorax, potentially mediated through anti-inflammatory and metabolic benefits. These findings support the broader role of GLP-1 RAs in mitigating infection-related complications in diabetes care. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.